Literature DB >> 15569367

Pathological validity of esophageal endoscopy. How real is what we see? Myth or reality?

R Kanthan1, B Torkian, S C Kanthan.   

Abstract

The purpose of this study was to characterize the spectrum of esophageal pathology at a provincial tertiary care hospital and to evaluate these findings with their respective endoscopic diagnoses. The pathology slides of 183 esophageal biopsies for the year 2000 were reviewed and classified as esophagitis, intestinal metaplasia, low or high grade dysplasia, adenocarcinoma, squamous cell carcinoma or normal. One hundred and fifteen cases (63%) had complete concordant results with respective endoscopic reports. Sixty-eight cases (37%) had discordant results with inaccurate recognition of Barrett's esophagus in 9% and of esophagitis with a false positive in 16% and false negative in 7%. Although esophagoscopy remains a primary investigative tool in gastroesophageal diseases, evaluation of erythema, inflammation and esophagitis can be misleading. Pathologically confirmed esophagitis can occur in a 'normal' esophagus. Accurate endoscopic recognition of short-segment Barrett's remains a diagnostic challenge.

Entities:  

Mesh:

Year:  2004        PMID: 15569367     DOI: 10.1111/j.1442-2050.2004.00430.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  3 in total

1.  Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND.

Authors:  Craig G Chang; Edward Perez
Journal:  Obes Surg       Date:  2009-09-15       Impact factor: 4.129

Review 2.  Benign, premalignant, and malignant lesions encountered in bariatric surgery.

Authors:  Rao S Raghavendra; Dr Kini
Journal:  JSLS       Date:  2012 Jul-Sep       Impact factor: 2.172

3.  Esophageal abnormalities and the risk for gastroesophageal cancers-a histopathology-register-based study in Sweden.

Authors:  Isabella Ekheden; Jonas F Ludvigsson; Li Yin; Peter Elbe; Weimin Ye
Journal:  Eur J Epidemiol       Date:  2022-01-03       Impact factor: 12.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.